I. INTRODUCTION

C
LINICIANS are routinely faced with the practical challenge of integrating high-dimensional clinical data to recommend the most appropriate clinical decision for a given patient [1] . As the understanding of complex diseases progresses, the types of available tests and treatments diversify and, as a result, the difficulty of recommending the optimal clinical decision for particular patient increases as well. Current clinical decisions continue to rely on clinical practice guidelines which, in cases where scientific analysis and evidence is scarce, are mostly based on clinical experience and opinion. Also, current clinical practice guidelines are aimed at a "representative" patient rather than an individual patient who may display other relevant characteristics. Such "representative" guidelines may, thus, miss the opportunity to consider personal traits when recommending clinical decisions [53] - [56] . For example, the American Cancer Society (ACS) recently issued new guidelines which suggested that women with an average risk of breast cancer should start having mammograms at an age of 45 (five years later than ACS had previously recommended) [2] . However, women who have certain risk factors (family history of breast cancer, no children, etc.) have a higher risk of developing breast cancer, and they would benefit from having mammograms at an earlier age. In cases such as these, the ACS guidelines recommend that a high-risk patient consult with her physician to determine an appropriate screening age and interval, which is based on that particular physician's experience and opinion. Moreover, statistics show that diagnostic errors result in 10% of patient deaths and represent the most frequent type of medical malpractice claims in the United States [3] . This reality highly underscores the urgent need for building smart clinical decision support systems (CDSS) and diagnosis decision support systems (DDSS) that can assist clinicians in making accurate personalized clinical recommendations [4] . It has been recently recognized [5] that medical informatics tools and machine-learning techniques can be successfully used to provide recommendations for personalized diagnosis and treatment.
The goal of this paper is to develop methods that will enable CDSS and DDSS to personalize their recommendations based on individual patient characteristics. The wealth of information being routinely collected as a part of the electronic health record (EHR) provides an unprecedented opportunity to discover appropriate clinical recommendations for patients given historical information about the clinical decisions administered to similar patients and their actual outcomes [6] . However, using this information is difficult precisely because there is so much of it. The solution is to extract only the relevant information for the particular patient and the relevant clinical decisions previously used for similar patients among the wealth of available information. Extracting only the relevant information is important because using irrelevant features can significantly hurt the performance of the system, unnecessarily increase its complexity, and decrease its learning/adaptation speed [7] . Furthermore, the efficient discovery of relevant patient features can help clinicians focus on the relevant information available about the patient without having to sift through a large patient record.
In this paper, we present a novel approach called discovery engine (DE) which optimizes clinical recommendations by identifying the features in the patient record that differentiate the individuals who receive a certain clinical decision and respond positively from those who do not. Our approach utilizes the available contextual information about patients and learns from the large quantities of observational clinical data to inform clinical recommendations and make better decisions by learning from similar patients. We show that our DE approach consistently outperforms existing state-of-the-art machine-learning algorithms both regarding matching individual patients to the optimal treatment regimens as well as diagnosis accuracy.
One of the biggest challenges faced by this class of recommendation systems is that the rewards/actual outcomes of clinical decisions (e.g., five-year recurrence-free survival) are usually not available [8] , [52] . Moreover, even if rewards/actual outcomes of the clinical decisions were available, the counterfactuals-rewards/actual outcomes of alternative clinical decisions that were not used-are never available [52] . What is available, however, is a large medical literature that reports the results of a wide range of clinical studies, including different types of patients, different patient characteristics, different types of clinical decisions, and the actual outcomes of these decisions. We use the results of these studies to construct transfer rewards, which we use as proxies for rewards. This allows us to train the DE algorithms as well as to evaluate their performance in comparison to existing methods when the actual outcomes cannot be achieved. The four primary contributions of this paper are as follows:
1) We describe a novel approach for discovering the most relevant information from the EHR that distinguishes between patients that should receive one particular clinical decision and the patients who should be given another. For instance, premenopausal breast cancer patients are more likely to respond to a specific type of chemotherapy such as CEF [9] . 2) Using the past records in the EHR and external knowledge from the medical literature, our approach discovers the optimal personalized clinical decision based on the discovered relevant information (e.g., their clinical test results, treatment history, and outcomes). 3) In lieu of having actual reward values associated with clinical decisions, we define the transfer rewards, a method for estimating actual outcomes described in external knowledge (published literature and clinical practice guidelines) based on their similarities to individual patients given reported characteristics. 4) We apply DE to two medical applications: a) Personalized treatment recommendations (chemotherapy regimens) for breast cancer patients and b) diagnosis of breast cancer. DE is used to discover which features are relevant to make a distinct clinical decision and then uses this knowledge to build a clinical decision recommendation system. We evaluate the performance of DE in the context of breast-cancer diagnosis and treatment and show that it consistently and significantly outperforms state-of-the-art machine-learning algorithms.
II. RELATED WORKS
A. Personalized CDSS
Current medical practice relies on manually curated systematic reviews of the available scientific evidence and clinical guidelines that provide recommendations for large groups of patients rather than personalized recommendations that are tailored to individual patients. CDSS have been proposed before, but many of them do not consider the specific characteristics of patients and do not provide personalized clinical recommendations; hence, they are not very accurate and have only limited applicability in practice [10] , [11] , [53] - [56] . Moreover, clinicians often refer to the medical literature available through Medline/PubMed, VisualDX, and UpToDate to help them associate observed finding with possible conditions and recommended decisions. However, these resources are also not customized to a specific patient's case.
Several CDSSs are currently implemented and used in clinical settings. For instance, WizOrder was developed to help reduce medical errors and support clinical decisions when entering orders [61] . This system is now used in several neonatal intensive care units at Vanderbilt University Hospital. Assessment and treatment of hypertension: evidence-based automation (ATHENA) is a CDSS used to manage hypertension in primary care [62] . It was developed to recommend drug therapies and assess and control their effect on blood pressure. ATHENA is now used in several clinics in Northern California. TherapyEdge-HIV is a web-based real-time alerting system for the treatment of HIV, which is used in over 42 clinical sites [63] . While several CDSS are now implemented in clinical settings, their evaluations are often mixed. Some papers argue that CDSS significantly improve the effectiveness of clinical practice [59] , [60] , while others conclude that CDSS do not affect mortality and may even moderately increase morbidity outcomes [57] . Furthermore, the cost effectiveness of CDSS has yet to be demonstrated [58] .
The advent of Big Data has been identified as an opportunity to improve the performance of existing CDSS as well as catalyze the development of new CDSS [12] . A large literature has used data-driven approaches to developing representative rather than personalized healthcare decision support systems [13] . A smaller literature is dedicated to develop personalized CDSS. However, most existing papers in this strand of literature [14] - [20] only either just discuss opportunities rather than propose a concrete algorithm, or they apply off-the-shelf machine-learning techniques to the considered medical problem and do not address the unique characteristics and challenges of developing personalized CDSS. DDSS have been developed for cardiovascular diseases and diabetes using ensemble learning [21] , SVMs [22] , artificial neural networks [23] , or rule-based algorithms [24] . Although some DDSS issue accurate diagnostic recommendations for specific diseases, most of them are based on a small number of manually selected features [25] , [26] . Whenever the number of features (contexts) is large, these methods fail to perform well [27] .
Most importantly, most of the proposed CDSS solely focus on diagnosis recommendations and do not provide solutions for the equally important problem of treatment recommendations. A small number of studies attempt to propose CDSS for treatment recommendations [28] . However, these CDSS differ significantly from our DE. For instance, Tsopra et al. [29] propose antibiotic recommendation systems for representative patients but does not use a data-driven approach, and Zhang et al. [30] propose a CDSS for personalized medicine recommendations, but which uses similarity information among drugs and patients that is specific to the study at hand and cannot be easily applied to other diseases-the similarity between patients is solely based on the ICD nine codes and the similarity between drugs is based on their chemical structure. Hence, the methods in [29] and [30] are not widely applicable to a diverse set of patients and treatments.
In contrast, although our DE was only verified in the context of breast cancer so far, it is designed to operate in a variety of complex diseases, such as breast cancer, lung cancer, prostate cancer, etc. Furthermore, as we will show in our experimental section, it can perform well even when the number of features used to make a decision is large because it adopts a novel method to discover the most relevant features to consider when deciding on certain diagnosis or treatment options for a specific patient. For this, we developed a customized feature selection and decision-making system which significantly outperforms existing off-the-shelf techniques. Importantly, based on the authors' knowledge, DE is the first personalized CDSS able to discover which specific features of a patient are indicative of treatment success in a complex disease such as breast cancer.
Our study is also related to other works in the field of medical informatics dedicated to improve breast cancer diagnosis and treatment. However, our study is distinct from prior works, which only analyzed the impact of specific patient features (such as genetic information or imaging information extracted from mammograms or other imaging) to improve the performance of CDSS [31] - [33] . Our DE system is based on a novel set of machine-learning methods developed especially for personalized diagnosis and treatment discovery which are shown in later sections to significantly outperform existing methods that are generic. Moreover, DE is not only applicable to breast cancer, but can be generally applied to discover personalized treatment for other complex diseases.
B. Relevant Feature Selection
Another strand of the literature related to this study is relevant feature selection algorithms including correlation feature selection (CFS) and mutual information feature selection (MIFS) [34] , [35] . These are related to our feature selection approach. However, our clinical decision-dependent feature selection (CDFS) algorithm is very different from existing feature selection algorithms which focus on the patients' characteristics and not on how these characteristics distinctively impact different clinical decisions. Our approach is capable of discovering which different features are relevant to each different clinical decision. This makes CDFS similar to our prior work [36] , [37] -the RE-LEAF algorithm. However, unlike RELEAF, which is very slow because it must compare all possible combinations of features, CDFS can discover the relevant features in a very fast and efficient manner because it adopts a sequential feature selection approach. This sequential approach significantly reduces the sample and computational complexity of the RELEAF algorithm.
C. Machine-Learning Techniques
Our method also exhibits similarities to the contextual multiarmed bandit (MAB) problem. However, contextual MABs are very inefficient when the number of contexts (in our case patient features) is large (see the experimental section of [37] ). DE is able to successfully deal with the curse of dimensionality by discovering what information is relevant and making clinical decisions based only on relevant contexts rather than the entire set of contexts that can be extracted from the EHR, much of which is irrelevant to the decisions of whether to administer a specific treatment or not.
III. SYSTEM MODEL
In this section, we introduce our method-DE. The DE discovers/learns which features/characteristics of a patient are most informative in predicting the success of a clinical decision. For instance, the tumor grade may be found to be relevant for predicting the success of a certain type of chemotherapy in a patient, but not the success of another type of chemotherapy. Thus, different features may be discovered to be relevant for different decisions. Then, when a clinician requests the recommendation from DE for a specific patient, DE decides the best clinical recommendation for the patient which has the best-estimated outcomes. The outcome of a decision is estimated based on the values of the relevant features (i.e., the features found to be relevant for that decision) of the patient. For instance, if the tumor grade was found to be relevant for a certain chemotherapy that chemotherapy will or will not be recommended to that patient depending on that patient's tumor grade. 
N n =1 be the information available for the N previously seen patients. This represents the training set.
The outcomes of a clinical decision a do not depend on all the features [39] , [40] : we assume that the outcomes of a clinical decision a rely only on a subset of features R(a) ⊆ F which we call the relevant features. Let R = ∪ a A R(a) be the set of all relevant features. The DE approach is capable of discovering different features that are relevant to different clinical decisions. We say that R(a) is relevant/informative for clinical decision a if the expected reward only depends on the information contained in R(a).
Our goal is to discover the relevant features of each clinical decision a (this may be different for each decision), and recommend the optimal clinical decision that corresponds to the discovered relevant patient information. The optimal recommended clinical decision is given by
where E(·) is the expectation of the random variable. Therefore, a * (x R ) is defined as the clinical decision that yields the best expected patient outcome for a patient characterized by the relevant features x R .
IV. ALGORITHMS
DE consists of two algorithms: a CDFS algorithm and a clinical decision recommendation algorithm. As it can be seen in Fig. 1 , DE discovers different relevant features for different clinical decisions using CDFS. The detailed steps of each algorithm are described in the following sections, and the pseudocode of DE can be found in the online appendix [64] .
A. Clinical Decision-Dependent Feature Selection
To describe CDFS, we start by introducing a few notations. Letŷ a and N a be the sample mean rewards estimate and the number of patients who received the clinical decision a, respectively. Similarly letŷ S a (x S ) and N S a (x S ) be the sample mean rewards estimate and the number of patients (whose feature information contains x S and was provided clinical decision a), respectively. We formalize these variables as
where I {·} is the indicator function. We define the relevance metric h r f (a) as the variance of the rewards for a certain action a if a given feature x f is considered, when selecting the action: |ŷ
which represents the frequency with which feature x f is present when action a is selected. We formalize this as
Also, we define a redundancy metric h d f ,s (a) which measures how the expected reward made for a given patient is affected by considering an additional feature x f when clinical decision a is recommended. We formalize this as
(6) Then, we define U f (a) as the utility obtained if feature x f is additionally selected as a relevant feature for clinical decision a. LetR(a) be defined as the previously discovered relevant features set for clinical decision a. Then, the utility function
where 1/|R(a)| is used as a normalization factor. The main steps of the CDFS are outlined below:
Step 1: For each clinical decision a, initializeR(a) as the empty set (i.e., ∅) and its complementary set (R c (a)) as the set of all features (i.e., F ).
Step 2: The algorithm selects the first relevant feature which maximizes the relevance metric (h r f (a)), i.e., G = arg max
Step 3: The algorithm finds the subsequent relevant feature that maximizes utility function (U f (a)), i.e.,
Step 4: The algorithm iteratively runs Step 3 until the utility function U f (a) is less than threshold cost C, where C is an input parameter for the algorithm which can adjust the number of relevant features for each clinical decision, i.e.,
Discovered relevant features are used to recommend the optimal clinical decision in clinical decision recommendation algorithm.
B. Clinical Decision Recommendation Algorithm
The proposed clinical decision recommendation algorithm recommends the optimal clinical decision which maximizes the estimated patient outcome only based on the relevant contexts (features) discovered by CDFS. The main steps of the recommendation algorithm are outlined below.
Step 1: Find the set of unresolved clinical decisions (U) for the patient with information vector xR (a) :
where C TH · log (n) is a control function. C TH is an input parameter which can adjust the tradeoff between the confidence of the clinical recommendations and the learning speed of DE. 
This optimization selects the clinical decision with the maximum estimated reward for the patient with relevant information vector xR (a) . After the rewards of the recommended clinical decision are obtained, NR
(xR (â) ) are updated as follows:
The computational complexity of DE is O(ND 2 ); hence, DE has a relatively low run-time complexity with highdimensional datasets.
C. DE With Missing Information
EHR, more often than not, may have missing information for some patients [52] ; hence, DE must be able to operate properly even with missing information.
Suppose that the dataset contains missing information. We can divide the feature information vector x into two components: the available features (x av ) and the missing features (x m ). Thus, x = {x av , x m }. First, the relevance metric of CDFS is solely computed based on the available information
Therefore, if the feature f is frequently missing, h f (a) decreases, and as a result, the feature f is rarely selected as a relevant feature.
Second, it should also be noted that we can estimate the reward (ŷR , for each clinical decision a. More specifically, it can be estimated aŝ
We can estimate the conditional probability,
), based on the probability distribution of the features in the training set. Based on this estimation rule, we can robustly identify the optimal clinical decision even if there is missing information. 
V. TRANSFER REWARDS
As discussed in Section I, the most valuable rewards for most CDSS are, in theory, the actual patient outcomes (e.g., Fiveyear survival rates or recurrence rates in the case of breast cancer). However, these outcomes are very difficult to obtain in practice [52] . Instead, we use a proxy for outcomes based on external knowledge which consists of published literature and clinical practice guidelines. We refer to all external knowledge simply as references in the remainder of this paper.
The idea is to match patients to appropriate relevant references. For each patient and each reference, we define the term similarity as the amount of information that reference provides about that patient. The similarity is computed by calculating the posterior probability of that patient feature belonging to the population demography from the reference. Then, we aggregate the actual outcomes of certain clinical decisions for each reference according to the similarity (posterior probability) and use this as a transfer reward for that clinical decision when applied to that patient. The system model for transfer reward estimation is illustrated in Fig. 2 .
To compute the transfer rewards, we first estimate the similarity between a patient and a reference. The first step of estimating this similarity is to find the relevant patient features for each reference; we do this using a sequential feature selection algorithm based on the mutual information in order to deal with population demography [35] . The mutual information between the ith reference (E i ) and the kth feature (f k ) is defined as
where P (x|E i ) is the probability of feature x in reference i, P (x) is the probability of feature x across the entire set of references, and χ k is the context space of f k . LetR(E i ) be defined as the discovered relevant feature set for reference E i and the utility function U f (E i ) is determined as
where 1/|R(E i )| is used as a normalization factor. This utility function measures an increment of mutual information between relevant feature set and the reference when feature f is the additionally selected as relevant feature.
The algorithm selects the first relevant feature which maximizes the mutual information with E i , i.e.,
Then, the algorithm finds the subsequent relevant feature that maximizes utility function U f (E i ), i.e.,
The algorithm iteratively adds new relevant features inR(E i )
until the maximum utility function U f (a) becomes less than zero.
The second step is to compute a posterior probability of a patient feature set belonging to the population demography from the reference. Given the nth patient, characterized by the feature vector x n = {x 1 (n), . . . . . . x D (n)}, we compute the posterior probability that the given patient belongs to the population demography of the reference; we express this value as P (E i |X 1 = x 1 (n), . . . , X D = x D (n)). We compute this via Bayes rule; it is computationally convenient to take logarithms
where we write P (E i ) as the probability of selecting the ith reference as the best clinical decision for the entire population. We define this approximation of posterior probability as a similarity between nth patient and ith reference (Sim E i (x n )). Second, we compute the estimated transfer reward of each clinical decision a for nth patient as a weighted sum of actual outcomes of clinical decisions in each reference according to the similarity (Sim E i (x)), i.e.,
where r(a|E i ) is an actual patient outcome for clinical decision a in ith reference, ( Sim a|E i (x)) is a normalized similarity for clinical decision a, and A(E i ) is the set of clinical decisions (x) ). These provide a complete ranking of each clinical decision for each patient. The clinical decision with the highest transfer reward is the optimal clinical decision for the given patient. The pseudocode for estimating transfer rewards is given in the online appendix [64] .
VI. EXPERIMENT I: CHEMOTHERAPY RECOMMENDATION FOR BREAST CANCER PATIENTS
While our DE algorithm can be applicable, in general, CDSS, in this section, we illustrate its use in the context of a personalized recommendation system of chemotherapy regimens for breast cancer patients in this section. Fig. 3 shows the system model of this application. Table I summarizes the specific chemotherapy regimens as the codes.
A. Data Description
From an initial set of 2353 references (performing a narrow search of breast cancer chemotherapy regimens using PubMed Clinical Queries), 32 references were selected for further analysis. (The complete list of the 32 references is provided in the online appendix [64] .) The list was compiled based on the following two criteria: (1) References contain the clinical outcomes for at least one of the six standard chemotherapy regimens for breast cancer patients [7] , [42] , [43] ; (2) References include the demographic information of the breast cancer patients enrolled in the randomized trials. The sample size of reported references ranged from 50 to 3934 individuals. There was no crossover of individual subjects between these references. A summary of the population demographics, chemotherapy regimens, and actual outcomes in references is provided in the online appendix [64] .
We evaluate our DE algorithm and benchmarks on the deidentified database of 10 000 breast cancer patients which was created based on the patients participating in the National Surgical Adjuvant Breast and Bowel Project in the United States and Canada. The patients were diagnosed with operable and palpable breast cancer by core needle biopsy or fine needle aspiration. The patient data are characterized by 15 features summarized in Table II , and those are also corresponding with the patient features in 32 references.
We iteratively evaluated the performance of the algorithms based on ten rounds with ten different training sets and reported the average performance as a final performance of each algorithm. In each round, we used a randomly selected training set of 4000 patients among 10 000 entire patients and a disjoint testing set of 6000 patients. In other words, no training data were used during testing of the model, but ten different models were used to derive the average performance. We select 4000 patients to be in the training set since the performance of all algorithms (besides ACL) saturated beyond this number of patients.
B. Benchmarks
We compare the performance of DE with nine state-of-theart classification algorithms, ensemble learning algorithms, and feature selection algorithms which are widely used in CDSS and also commonly used benchmarks in medical and machinelearning references: 1) CFS: a well-known feature selection algorithm [34] ; 2) all Contextual Learning (ACL): a well-known contextual learning algorithm which uses all features. This is a modified offline version of the contextual bandit algorithm of Slivkins [41] ; 3) multivariate logistic regression (Logit); 4) linear regression (Linear); 5) multivariate support vector machines (SVM); we use a radial basis function (RBF) kernel SVM; 6) SVM with feature selection (SVMs-f) [38] ; 7) adaptive boosting (AdaBo); 8) classification tree (CTree); 9) regularized multivariate logistic regression using lasso (ReLog); 10) regularized linear regression using lasso (ReLin);
C. Success of the Optimal Chemotherapy Recommendation for Breast Cancer Patients
Given a patient, both our algorithm and the benchmark algorithm recommend a chemotherapy regimen corresponding to particular references. If the recommended chemotherapy has the highest estimated transfer reward for the patient among all six chemotherapy regimens, we regard the algorithm in question as making the correct recommendation for that patient; i.e., it has recommended the best course of treatment. (Notice that the best course of treatment may not promise a good outcome: some cancers are not treatable.) We take the fraction/percentage of correct recommendations to be the success rate for the algorithm in question.
Given the success rate for the algorithm, we apply two performance metrics: the simple percent agreement and the Cohen's kappa coefficient [44] . Simple percent agreement (p 0 ) is the success rate (the fraction of times the personalized treatment prediction coincides with the recommendation provided in the medical literature for the patient). Cohen's kappa coefficient (κ) is a metric which measures interrater agreement. It is usually considered a more robust measure than a simple percent agreement (p 0 ), because κ measures the improvement over chance agreements. If p e is the probability of agreement by chance, then kappa coefficient is defined as κ = p 0 −p e 1−p e . The bar graphs in Fig. 4(b) show that the first chemotherapy recommendation of DE is successful (as defined above) 73.4% of the time, and Fig. 4(c) also shows that one of the first two recommendations is successful 88.4% of the time. This is 7.7% better than the second-best approach (SVM) regarding selecting the optimal chemotherapy on its first choice, and 5.6% better regarding matching the optimal chemotherapy within the first two choices. This is already a significant improvement; however, regarding kappa coefficients, the improvement is even greater: DE works 16.6% better than SVM, which is described in Fig. 4(a) . This is because SVM indiscriminately recommends the popular chemotherapies and is not robust when classifying the less popular chemotherapies. Given robustness considerations, which are essential in medical treatment recommendations, kappa coefficients are more often used as a performance metric in medical informatics.
When comparing our algorithm with other algorithms that rely on feature selection, we again see a significant improvement. Again, note that while other algorithms use feature selection, they do not select relevant features for specific chemotherapies, and it is through this selection that our algorithm achieves improvement. CFS achieves only a 48% of simple percent agreement because it cannot use the efficacy of the chemotherapy to discriminate the relevant features, and, hence, the technique is entirely unsupervised. ACL succumbs to the "curse of dimensionality" because there are 15 features with different ranges, resulting in over 7 million combinations to explore. Logistic regression, linear regression, and SVM perform worse than DE because they do not consider the relevant features for selecting chemotherapies at all. Table III shows the top four ranked relevant features discovered by CDFS-tumor stage, positive axillary lymph node number (PLNC), estrogen receptor, etc.,-for recommending AC, ACT, AT, CAF, CEF, and CMF chemotherapy. As it can be seen from Table III, CDFS can discover the different relevant features that are relevant for different chemotherapy regimens.
D. Relevant Features for Each Chemotherapy
It is important to note the features discovered by DE are indeed confirmed to be relevant by clinical studies. First, note that the six considered chemotherapy regimens are commonly recommended to node positive breast cancer patients, i.e., patients where cancer has been found in the lymph nodes [43] . It is critical to know whether lymph nodes are positive or negative. PLNC tells us both the number of nodes and whether lymph nodes are positive or negative. For instance, zero PLNC implies node negative breast cancer, while otherwise indicates nodepositive breast cancer. Hence, PLNC is selected as a relevant feature by CDFS. Second, the menopausal status is considered important because medications affect cancer differently in premenopausal and postmenopausal women [9] . More specifically, the CEF chemotherapy is only recommended for premenopausal women. Although the menopausal status is not included in this relevant feature set, women over the age of 50 are usually considered postmenopausal [9] . Therefore, age was correctly identified by DE to be a discriminative feature for selecting among chemotherapy regimens. Third, tumor stage is another important feature to consider when deciding among chemotherapy regimens as described in [42] . Medications A(Doxorubicin), T(Taxotere), and E(Epirubicin) are recommended for advanced breast cancer and our top six chemotherapy regimens include more than one of these medications. Therefore, DE has correctly discovered that the features that are relevant for these chemotherapy regimens contain tumor stage information. Finally, the medication T(Taxotere) is usually recommended to breast cancer patients who do not respond to their current chemotherapy. Thus, the prior chemotherapy information is correctly discovered by DE to be relevant for AT and ACT therapies.
E. Performance When Patient Information is Missing
As explained before, patient information is often missing from the EHR. Moreover, studies have shown that the missing information is often not random [45] . For example, the age of the patient is easy to record, and blood pressure is often verified several times by a nurse when a patient is seen by a clinician, so it is typically neither missing nor incorrect. However, HER2NEU may not be recorded depending on the diagnostic tests ordered and capabilities of a medical center. Fig. 5 describes the performance of DE when features are missing with various rates. It shows the performance degradation of DE and the benchmark algorithms as a function of the average degree of incompleteness [45] . We did not use the percentage of missing features as a metric since the features are not randomly missing. The percentages of missing features corresponding to each degree of incompleteness are described in the online appendix [64]; these percentages were computed based on statistics extracted from medical records of patients. Fig. 5 shows that the performance of DE degrades from 73.4% to 63.0% (when the average degree of incompleteness is 50%). However, even with missing information, DE continues to outperform the other methods. DE discovers relevant features with low missing probability and can estimate the missing feature information based on the available feature information. As a result, the impact of missing information is minimized. In fact, DE performs better than most other algorithms even when DE misses significant amounts of information from the EHR while the other algorithms make their decision with full information. Hence, we can indeed see that the performance of DE is robust even when information is missing.
VII. EXPERIMENT II: DDSS FOR BREAST CANCER PATIENTS
In this section, we illustrate how the DE algorithm can be used for breast cancer diagnosis. In this case, we can directly use patients' actual outcomes as the rewards. Fig. 6 describes the system model of this application.
A. Data Description
In this section, we evaluate the performance of DE for breast cancer diagnosis using the UCI Diagnostic Wisconsin Breast Cancer Database [46] . The dataset contains 30 patient features extracted from needle biopsy features, such as radius, compactness, or smoothness of tumor cell nucleus. Table IV summarizes the details of 30 patient features. The number of instances in this dataset is 569 and the diagnosis (label) for each instance is either malignant or benign. 
B. Benchmarks
We compare the performance of DE in this clinical setting with all the benchmarks describes in Section VI-B. Also, we add three existing state-of-the-art feature selection algorithms as the benchmarks to compare the performance of our feature selection algorithm (CDFS) separately. 1) MIFS: a well-known feature selection algorithm based on mutual information [35] ; 2) relevance learning with feedback (RELEAF): an actiondependent relevance learning algorithm based on the expected rewards [36] , [37] ; 3) principal component analysis (PCA): a statistical procedure to discover linearly uncorrelated variables based on orthogonal transformation [47] 
C. Experiments Setup
First, we compare our DE algorithm against state-of-the-art machine-learning algorithms: logistic/linear regressions, RBF kernel SVM, adaptive boosting algorithms, CTree and regularized logistic/linear regressions. We use tenfold cross validation to evaluate the performance of algorithms. We performed ten independent cross validation runs and reported the average performance of ten runs.
To highlight the impacts of CDFS, we performed two additional sets of experiments. In the first set, we compared the performance of our DE system using CDFS with the performance of the DE system where CDFS was replaced with one of the four different feature selection algorithms: CFS, MIFS, RE-LEAF, and PCA. This comparison shows the impact of CDFS on the overall performance of the DE. Other experiment settings are the same as the first experiment.
In the second set of additional experiments, we use our feature selection algorithm CDFS in conjunction with the diagnostic recommendation made by the benchmark algorithms-linear regression, logistic regression, SVM-to highlight the specific impact of our feature selection algorithm. Other experiment settings are the same as the first experiment.
D. Performance of Diagnostic Recommendation for Breast Cancer Patients
Given a patient, DE and the other benchmark algorithms classify the tumors as malignant or benign. To quantify their performance, we apply three different performance metrics: the prediction error rate (PER), the false positive rate (FPR), and the false negative rate (FNR). PER is defined as the fraction of times the recommended diagnosis of our algorithm is different from the actual label. FPR and FNR are defined as the diagnosis error rate for benign instances and malignant instances, respectively. The main goal of DDSS is to minimize the FPR given an allowable threshold for FNR as selected by the clinicians. In practice, this is often set to be below 2% [25] . Therefore, in this experiment, the FNR threshold is also set to be 2%. Using this threshold, we can characterize our performance metrics as follows:
minimize FPR subject to FNR ≤ 2%
1) Comparison With Machine-Learning Algorithms:
As the Table V shows our DE algorithm has 2.23% PER and 2.62% FPR which is 2.18% and 4.20% better than the secondbest algorithm (SVM) when the tolerable threshold of FNR is set to below 2%. There are two reasons for the outstanding performance of the DE approach. First, our diagnostic recommendation algorithm yields high accuracy for classification, because 
2) Comparison With Feature Selection Algorithms:
In this section, we demonstrate the impact of the CDFS algorithm on the DE system. We compare the performance of the DE using CDFS with the performance of DE using different feature selection algorithms.
As seen in Table VI , CDFS outperforms all other feature selection algorithms when the tolerable threshold of FNR is set to below 2%. This is because CDFS is capable of discovering diagnosis relevant features based on their impact on the expected diagnosis accuracies. Although RELEAF also considers the dependence between diagnosis accuracy and feature selection, it is extremely slow when the number of features is large, as is the case for this and many other medical datasets. Furthermore, combinatorial approach (RELEAF) requires a relatively large amount of training sets to accurately discover the relevant feature, which is not the case for the medical dataset available to us.
Next, we replace DE's recommendation algorithms with various existing machine-learning algorithms to demonstrate the impact of the CDFS component of DE on the diagnostic decisions. As seen in Table VII , CDFS improves the performance of all benchmark algorithms because it can accurately discover and select the (different) features that are relevant for different diagnosis.
E. Relevant Features for Diagnostic Decision
Table VIII shows the top five ranked relevant features discovered by CDFS-worst perimeter, concave points concavity, radius, and area, etc-for diagnosing malignant or benign cancer among all of the features summarized in Table IV . As seen [48] state that the three most important factors to diagnose tumor cell nuclei as malignant or benign are the relative size ratio between nucleus and cytoplasm, irregular shape, and irregular chromatin. However, because chromatin feature information is not available in our dataset, only the relative size and irregular shape can be potential candidates as the relevant features. The size-related features are radius, perimeter, and area, and the shape-related features are the concavity and concave points [49] . The top five features found to be relevant by DE to classify malignant and benign tumor cell nuclei are all related to the tumor shape and relative size, which is in accordance to [50] . Features such as texture, smoothness, compactness, symmetry, and fractal dimension are not found to be relevant by DE and are not mentioned as important features in [51] . Hence, we can conclude that DE can discover the relevant features for making a correct diagnosis without prior medical knowledge.
VIII. DISCUSSION AND FUTURE WORKS
We proposed a novel approach that discovers the most relevant information from the EHR to determine which clinical decision to recommend for a patient. Furthermore, our approach uses this information to provide personalized recommendations to assist physicians in their decision-making process. Our results demonstrate that DE outperforms existing machine learning, prediction, and feature selection methods in both CDSS and DDSS applications. These superior recommendations are extremely important because they have the potential to prevent medical errors, and, thus, improve the quality of medical care. We also showed that our method is robust against missing information, which is important in numerous clinical settings.
Future work will consider that feature information (such as the tumor size, PLNC number, and tumor radius in the case of a breast tumor) may change over time. The time dependence may also influence the duration of a therapy and the selection of future therapies. Another DE extension will consider the global sequence of treatment decisions that optimizes long-term outcomes (e.g., overall survival rate or five-year recurrence rate).
In conclusion, we believe that our proposed contextual learning approach demonstrates promise toward providing useful personalized clinical recommendations. As new types of treatment are evaluated and approved for medical use, clinicians will have an increasingly difficult time determining which clinical decisions are most effective for individual patients. DE provides a pathway toward providing computational methods for personalized clinical decision recommendations.
